Multi-Imaging Characterization of Cardiac Phenotype in Different Types of Amyloidosis
Adam Ioannou(MACOM (United States)), Marianna Fontana(The Royal Free Hospital), Daniel Knight(MACOM (United States)), Peter Kellman(National Institutes of Health), Helen J. Lachmann(Royal Free London NHS Foundation Trust), Liza Chacko(The Royal Free Hospital), Ashutosh Wechelakar(MACOM (United States)), Lucia Venneri(MACOM (United States)), Philip N. Hawkins(The Royal Free Hospital), James Brown(MACOM (United States)), Charlotte Manisty(National Institutes of Health), Brendan Wisniowski(The Royal Free Hospital), Rishi Patel(MACOM (United States)), Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), Carol Whelan(Boston University), Yousuf Razvi(MACOM (United States)), Aldostefano Porcari(University of Trieste), Tushar Kotecha(Royal Society), Ana Martinez–Naharro(Children's Cancer and Leukaemia Group), James Moon(Virginia Mason Medical Center)
Cited by 53
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
NALP3 Forms an IL-1β-Processing Inflammasome with Increased Activity in Muckle-Wells Autoinflammatory Disorder
|Immunity|2004|1.7k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k